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Integrin a6b4 is a hemidesmosomal transmembrane
molecule involved in maintaining basal cellmatrix
adhesion through interaction of the large intracytoplas-
mic tail of the b4 subunit with the keratin intermediate
¢lament network, at least in part through its binding
with plectin and BP180/type XVII collagen. Here we
report a patient with predominant features of epider-
molysis bullosa simplex due to a mutation in the integ-
rin b4 gene. The patient, a 49-y-old female, had mild
blistering of hands and feet from birth on, dystrophy
of the nails with onychogryposis, and enamel hypopla-
sia. She had no alopecia and no history of pyloric atre-
sia. Electron microscopy and antigen mapping of a skin
blister revealed that the level of separation was intraepi-
dermal, low in the basal keratinocytes through the at-
tachment plaque of the hemidesmosome. Immuno-
£uorescence microscopy revealed absent binding of
monoclonal antibody 450^11 A against the third ¢bro-
nectin III repeat on the intracellular domain of integrin
b4, whereas binding was reduced with monoclonal
antibodies recognizing epitopes on amino-terminal
and carboxy-terminal ends of the polypeptide. At the
molecular level the phenotype was caused by a novel 2
bp deletion 4733delCT in ITGB4, resulting in in-frame
skipping of exon 36 and a deduced 50 amino acid dele-
tion (1450^1499) within the third ¢bronectin type III re-
peat in the cytoplasmic domain of the integrin b4
polypeptide. Immunoblot analysis demonstrated a 5
kDa shorter b4 polypeptide. The 4733delCT mutation
was heterozygously present in the DNA. The patient is
also expected to be heterozygous for a null allele, as no
full-size protein was detected in vitro and the epitope
450^11 A was absent in vivo. These data show that dele-
tion of the third ¢bronectin type III repeat in the cyto-
plasmic domain of integrin b4, which is thought to
interact with BP180/type XVII collagen, is clinically
pathogenic and results in a mild phenotype with predo-
minant features of epidermolysis bullosa simplex. Key
words: basement membrane/bullous disease/collagen/hemides-
mosome. J Invest Dermatol 119:1275 ^1281, 2002
E
pidermolysis bullosa (EB) is a heterogeneous group of
bullous disorders of the skin and mucous membranes
characterized by detachment of epithelium after min-
or friction. EB is classi¢ed into three main categories
according to the level of blister formation: simplex,
junctional, and dystrophic (Fine et al, 2000). In EB simplex
(EBS) the skin separates above the plasma membrane within the
basal cells, whereas in junctional EB (JEB) the cleavage occurs
below the plasma membrane within the lamina lucida of the epi-
dermal basement membrane zone (BMZ). EBS is caused by mu-
tations in the KRT5 and KRT14 genes coding for the basal cell
keratins 5 and 14 (Corden and McLean, 1996) and in the PLEC1
gene coding for the hemidesmosomal plaque protein plectin
(Uitto et al, 1996). JEB is a heterogeneous group of autosomal re-
cessive blistering disorders caused by mutations in genes encod-
ing structural components of the hemidesmosome, lamina lucida,
and lamina densa. Mutations underlying JEB have been identi-
¢ed in six di¡erent genes: the three genes that encode the a3,
b3, and g2 polypeptides of the laminin 5 complex (LAMA3,
LAMB3, and LAMC2) (Nakano et al, 2002), the COL17A1 gene,
coding for type XVII collagen, also known as the 180 kDa bul-
lous pemphigoid antigen (BP180) (Pulkkinen and Uitto, 1998),
and the genes encoding integrin a6b4 (ITGA6 and ITGB4)
(Nakano et al, 2001).
The last two components, type XVII collagen and integrin
a6b4, are transmembrane adhesion molecules of the hemidesmo-
some, which bridge the intracellular hemidesmosomal plaque
with the extracellular basement membrane matrix. Although
complete ablation of either transmembrane protein results in
junctional cleavage below the plasma membrane, it is conceivable
that abnormalities of the cytoplasmic domain may result in intra-
cellular separation consistent with a simplex type of split level,
and indeed, for type XVII collagen this was recently reported in
a patient with a genomic deletion in COL17A1 corresponding to
an in-frame deletion from the intracellular domain of the poly-
peptide (Huber et al, 2002). This patient not only had a predomi-
nant simplex type of cleavage but also a milder clinical
phenotype with features of EBS that lacked the abnormalities
more typical for JEB, such as alopecia, loss of eyelashes, and en-
amel defects. In this study we report a patient in whom deletion
of a cytoplasmic domain of integrin b4 also causes EBS.
Integrin b4 is predominantly expressed in strati¢ed squamous
and transitional epithelia, and within the cutaneous BMZ is loca-
lized to hemidesmosomes, which rely on the presence of this
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integrin for their formation.The a6b4 heterodimer is involved in
maintaining basal cell^matrix adhesion through interaction of
the large intracytoplasmic tail of the b4 subunit with the keratin
intermediate ¢lament network, at least in part through its bind-
ing with plectin and BP180/type XVII collagen. Also, the extra-
cellular domain of b4 integrin serves as a receptor for laminin 5
and interacts with the BP180, both of them being components of
the lamina lucida. For a review see Borradori and Sonnenberg
(1999).
Complete ablation of integrin b4 due to homozygous ITGB4
null alleles results in the lethal form of JEB associated with pylo-
ric atresia (JEB-PA, MIM 226730). Although there are nonlethal
forms of JEB due to ITGB4 missense mutations, almost all are
associated with pyloric atresia (Nakano et al, 2001). There is only
one report of a case with JEB due to ITGB4 mutations that was
not associated with pyloric atresia (Inoue et al, 2000). The patient
was homozygous for the G931D missense mutation in the cyto-
plasmic tail of integrin b4. This patient had the typical clinical
features of generalized atrophic benign JEB with progressive alo-
pecia, tooth defects, and nail dystrophy. The level of separation in
JEB-PA due to integrin b4 mutations is mostly within the lamina
lucida, but often epithelial remnants are present on the blister
£oor that are thought to be ‘‘torn-o¡’’ from the basal keratino-
cytes (McMillan et al, 1998). Actually, ‘‘pseudojunctional’’ splits
very low in the basal cells have been reported in JEB-PA patients
with mutations in the b4 gene (Mellerio et al, 1998; Pulkkinen
et al, 1998a), as well as in knock-out mice with ablation of
the ITGA6 or ITGB4 genes (Georges-Labouesse et al, 1996; Van
der Neut et al, 1996).
Here we report a remarkable EB case presenting with localized
blistering of the hands and feet without pyloric atresia due to a
mutation in the integrin b4 gene. The phenotype had predomi-
nantly features of EBS with intraepidermal blister formation. At
the molecular level the phenotype was caused by a novel 2 bp
deletion 4733delCT in ITGB4, resulting in in-frame skipping of
exon 36 and deletion of a cytoplasmic domain of the integrin b4
polypeptide.
MATERIALS AND METHODS
Patient characteristics The patient, a 49-y-old female, had from birth
on blister formation of the hands and feet after minor trauma. She is the
only child of a nonconsanguineous marriage and there is no family history
of EB. She did not conceive. Although the whole skin was fragile, such as
after the use of adhesive plaster, blistering was mainly restricted to the
hands (Fig 1A) and feet (Fig 1B). Blistering frequency increased during
the summer. The skin of the body was intact and normally pigmented.
Subungual blister formation from early infancy on had led to thickening
of nail plates (pachyonychia), distal onycholysis, and excessive curvature in
longitudinal and transverse directions (onygogryphosis) (Fig 1A). The
toenails were dystrophic (Fig 1B). The soles showed hyperkeratosis with
circumscript callous formation. Her teeth were characterized by the
absence of enamel since appearance and were all restored with crowns by
the age of 15. She had normal scalp hair, eye lashes, and eye brows, and
secondary hair was present. The right conjunctiva showed increased
vascular injection. There was no history of pyloric atresia or other
gastrointestinal or urinary problems related to EB.
Electron microscopy Skin biopsies were taken from healthy looking
skin, from lesional skin (left little ¢nger), and from a freshly rubbed
blister. Electron microscopy was performed as previously described
(Jonkman et al, 1992).
Antibodies and immuno£uorescence microscopy For immuno-
£uorescence microscopy on tissue samples, un¢xed cryostat sections of
snap-frozen skin biopsies were processed as previously described
(Jonkman et al, 1992). The following monoclonal antibodies were used:
pan-keratin with CK1 (Dako), laminin 5 with GB3, uncein with 19-DEJ-
1, type VII collagen with LH7:2, BP180/type collagen XVII endodomain
with 1A8c, BP180/type collagen XVII ectodomain with 1D1 and NCC-
Lu-226 (Yamada et al, 1996), plectin/HD1 with HD121, BP230 with 815,
integrin a3 with J143, integrin b1 with TS2/16, integrin a6 with GoH3,
integrin b4 ectodomain with 58XB4 and 439^9B, and the integrin b4
endodomain with 450^11 A (Kennel et al, 1991) and clone 7 (BD
Biosciences). More precisely, the epitope of the 450^11A monoclonal
antibody is located within the segment of the third ¢bronectin III (FNIII)
repeat (codons 1458^1541) on the b4 endodomain (personal
communication, Dr. Sonnenberg), whereas clone 7 recognizes an epitope
at the carboxy-terminal end. In combination with primary mouse
monoclonal antibodies we used Alexa 488-conjugated goat antihuman
IgG (Molecular Probes Europe, Leiden,The Netherlands) as secondary step.
Immunoblotting Preparation of cell extracts and immunoblotting was
as described before (Van Leusden et al, 2001). For detection of integrin b4
we used goat polyclonal antibody N-20 against the extracellular amino-
terminus (Santa Cruz Biotechnology, Santa Cruz, CA) and monoclonal
antibody 450^11A against the intracellular domain. Bound goat antibody
was detected by subsequent incubation with alkaline-phosphatase-
conjugated rabbit antigoat IgG and alkaline-phosphatase-conjugated goat
antirabbit IgG, and bound monoclonal mouse antibody by goat
antimouse IgG followed by alkaline-phosphatase-conjugated rabbit
antigoat IgG.
Cell culture, and DNA and mRNA isolation Keratinocytes were
isolated from skin biopsies and cultured in serum-free medium
(BioWhittaker, Verviers, Belgium) as described previously (Jonkman et al,
1997).Total RNAwas extracted from cells cultured for three passages using
Trizol (Gibco, Glasgow, U.K.), according to the manufacturer’s protocol.
Figure1. Clinical features of the patient. (A) Blister on the little ¢nger without milia or scarring. Dystrophy of the ¢nger nails with pronounced
onychogryposis of the thumbnail. (B) Dystrophy of the toe nails. Blisters heal with hyperkeratosis and depigmentation.
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DNA was extracted from cultured keratinocytes brie£y as follows: cells
were rinsed twice with phosphate-bu¡ered saline and lyzed in the culture
£ask with 150 mm NaCl, 10 mm ethylenediamine tetraacetic acid (EDTA)
pH 8.0, 1% sodium dodecyl sulfate, with gentle shaking for a few minutes.
The viscous supernatant was transferred to a clean tube, proteinase K was
added to 100 mg per ml, and the lysate was incubated at 601C for 16 h. After
extraction with phenol/chloroform high molecular weight DNA was
precipitated with ethanol or 2-propanol, washed with 70% ethanol, and
dissolved overnight in 10 mM Tris^HCl, 0.1 mM EDTA pH 8.0, under
continuous shaking.
Reverse transcription polymerase chain reaction (RT-PCR) and
identi¢cation of the mutation Nucleotide numbering, used
throughout this study for primer position and the site of mutation, is
based on the 41 exons containing mRNA (including exons 33 and 35)
and is relative to the start site of translation (accession number
NM_000213). Amino acid numbering is based on the integrin b4A splice
variant expressed in keratinocytes that lacks translation of exons 33 and 35
(accession number NP_000204).
Aliquots of total RNA from patient and control cultured keratinocytes
were reverse transcribed with M-MLV Reverse Transcriptase (GibcoBRL)
and oligo(dT) priming. Subsequently, ITGB4 cDNA was ampli¢ed with
overlapping primer sets (Table I) and analyzed on agarose gel. The
mRNA sequence from the public domain, used for primer development
and nucleotide numbering, was basically GenBank accession no. X53587,
with the 159 nucleotide exon 35 sequence from GenBank X52186
(nucleotides 4358^4515) inserted at position 4744^4745 of X53587. The
multiple bands in the patient’s cDNA due to aberrant splicing were
isolated from gel and cloned in vector pCRII (TOPOTM TA-cloning Kit,
Invitrogen). Di¡erent clones were isolated, analyzed by restriction
digestion and agarose gel electrophoresis, and subjected to automated
sequencing. In addition, genomic DNA was PCR ampli¢ed and
sequenced directly.
RESULTS
The ultrastructural level of separation was intracytoplasmic
Examination of skin specimens by electron microscopy showed a
normal number (81 per 40 mm BMZ, normal 71) of hypoplastic
hemidesmosomes (average diameter 117 nm, normal 7200 nm)
(Fig 2A) in uninvolved skin. The inner cytoplasmic plaque was
absent in 30% (normal 710%) of the hemidesmosomes,
coinciding with poor attachment of intermediate tono¢laments.
Biopsies of a¡ected skin and of a blister induced by rubbing
showed a plane of separation above the plasma membrane
through the hemidesmosomal plaque. Blistering started with
vacuolization in the cytoplasm of the basal cells (Fig 2B).
Immuno£uorescence microscopy of lesional skin con¢rmed
the cytoplasmic level of tissue separation Type VII collagen,
laminin 5, the ectodomains and endodomains of BP180/type
XVII collagen, the ectodomains of integrin a6, and the
ectodomains and endodomains of the b4 subunit lined the
blister £oor (data not shown). BP230 (Fig 3A) was
predominantly present in the blister £oor, whereas keratin
(Fig 3B) and plectin/HD1 (Fig 3C) were mainly found in the
roof of the blister. The cleavage level was thus extremely low in
the basal cell separating plectin that is localized on the attachment
plaque furthest inwards from the plasma membrane (Shimizu
et al, 1999) from those localized closer to the plasma membrane
(BP230, integrin a6b4, and BP180/type XVII collagen) (Ishiko
et al, 1993; Sato et al, 1998).
Table I. ITGB4 PCR primer setsa
Set Sense primer Exon Antisense primer Exon Size (bp)b
1 m155F: 50 -tgcagccccatctcctag 1 0817R: 50 -catcagcctcatagtggaag 8 973
2 0671F: 50 -ggatctcaggcaacctggat 7 1616R: 50 -tcatactcgcagaactgacc 13 945
3 1485F: 50 -ctctctgagtgacattcagc 13 2212R: 50 -aggcacagtacttccagcat 18 727
4 2091F: 50 -tgtcctggtgcacaagaaga 17 2667R: 50 -catcagcactgtgtccacaa 24 576
5 2488F: 50 -gagaacctgctgaagcctga 21 2880R: 50 -cagctgcttctcgtcgtcat 25 392
6 2701F: 50 -cttacagagaagcaggtgga 24 3694R: 50 -agacgacattgaaggccaga 30 993
7 3569F: 50 -gcgactatgagatgaaggtg 29 4395R: 50 -actggtcgtggtcatcctgt 34 616
8 4053F: 50 -tgacgttctacgctctccat 32 4954R: 50 -ggaacacgtaggagtggttg 37 532
9 4837F: 50 -tacagtgtggagtaccagct 36 5711R: 50 -aaggatggagtagctgagga 41 874
i35 4666F: 50 -cgagactctataatcctggc 35 4802R: 50 -cagctcactctgagagatgt 36 622
aPCR primer sets used for ampli¢cation of cDNA and genomic DNA. Primer names indicate the relative cDNA sequence position, with the start site of translation
chosen as position 1 (cDNA nucleotide numbering is with exons 33 and 35 inclusive).
bSizes in bp: sets 1^9 for cDNA ampli¢cation; set i35 for PCR on genomic DNA.
Figure 2. Electron microscopy. (A) Hypoplastic hemidesmosomes with
sparse tono¢lament projections in uninvolved skin. (B) Early blister forma-
tion with vacuolization in the cytoplasm of a basal cell. Note the tuft of
intermediate ¢laments (arrowhead) attached to hemidesmosomes.The blister
£oor is covered by plasma membrane (arrow). The lamina densa is indicated
by a dotted line. Bar: 1000 nm.
Figure 3. Immuno£uorescence antigen mapping reveals extremely
low intraepidermal level of separation. (A) BP230 mainly lined the
£oor of the blister. (B) Keratin was present in the blister roof and in an
extremely thin line on the blister £oor. (C) Plectin/HD-1was restricted to
the roof of the blister.
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Immuno£uorescence microscopy of nonlesional skin re-
vealed normal polarization of hemidesmosome components
except integrin a6b4 An antibody directed against the third
FNIII repeat on the intracellular domain of integrin b4 failed to
detect any epitope, even in nonlesional skin (Fig 4A), strongly
indicating ITGB4 as the site of mutation. Staining for the
extracellular part of integrin b4 with monoclonal antibodies
58XB4 (Fig 4B) and 439^9B was moderately reduced along the
epidermal BMZ, whereas staining for the intracellular tail with
monoclonal antibody clone 7 was in a normal linear pattern
severely reduced. Expression of integrin a6 was moderately
reduced and con¢ned to the epidermal BMZ (Fig 4C). The
expression of uncein, the monoclonal marker for JEB, was
severely reduced along the epidermal BMZ (not shown).
Plectin, BP230, integrin a3b1, and BP180/type XVII collagen
(Fig 4D) were normally distributed along the epidermal BMZ.
Shortened integrin b4 polypeptide in patient cells
Immunoblots from proteins extracted from cultured
keratinocytes showed that patient cells synthesize integrin b4 of
reduced size as shown by polyclonal antibody N-20 directed
against the extracellular domain (Fig 5). As expected, antibody
450^11 A, having its epitope within the third FNIII repeat in the
cytoplasmic domain, failed to detect any protein on immunoblot.
Mutational analysis demonstrates a heterozygous genomic 2
bp deletion resulting in skipping of exon 36 RNA was
extracted from keratinocytes derived from patient skin biopsies
and cultured for a few passages, and the ITGB4 mRNA was
analyzed by RT-PCRwith nine overlapping primer sets.Table I
summarizes the primer sequences and positions. Comparison
with control keratinocyte RNA showed no abnormal transcripts
except for the amplicon encompassing exon 36: three bands were
visible on agarose gel, one with apparently normal length, and
two shorter PCR products compared to the control
ampli¢cation. The shortest band was the most predominant one
(Fig 6). PCR fragments were isolated from gel, subcloned into
plasmids, and sequenced. The shortest fragment appeared to be
generated by skipping of exon 36, as the sequence was reading
from exon 34 directly into exon 37 (ITGB4 exon 35 normally is
absent in keratinocytes, as is exon 33). The in-frame skipping of
the 150 bp of exon 36 results in deletion of aa-1450 to aa-1499
corresponding to the beginning of the third ¢bronectin repeat
(1458^1541) in the intracellular domain of integrin b4 (Fig 7).
The sequence of a clone containing an insert of apparently
normal length, from the upper band (Fig 6), revealed a 2 bp
(CT) deletion in the sequence of exon 36 at position 4733
(CTGACTG(ct)DGGTGTG). PCR products from the band with
intermediate size were unclonable; these fragments most probably
were heteroduplex PCR products, as an intermediate band with
similar size could be generated when a mixture of two clones,
one with upper band insert and one with lower band insert, was
subjected to PCR (results not shown). Sequence analysis of PCR
ampli¢ed genomic DNA con¢rmed the 2 bp deletion (ITGB4:
4733delCT) and also showed that the patient was heterozygous
for this mutation.
DISCUSSION
The heterozygous presence of the 2 bp deletion in exon 36 of
ITGB4 in the patient was most probably accompanied by a null
allele. RT-PCR and subsequent sequence analysis revealed aber-
rant splicing of ITGB4 exon 36. Sequencing of a clone not de-
leted for exon 36 identi¢ed a 2 bp deletion at position 4733 in
exon 36. Sequence analysis of genomic DNA showed that this
mutation was heterozygously present in the patient.The mutation
leads to a frame shift and a premature termination codon (PTC)
at the second position of exon 37. The majority of RT-PCR pro-
duct resulted from mRNAwith skipped exon 36. Exon 36 is 150
bp in size and deletion does not destroy the open reading frame
but leads to a 50 amino acid deletion in the cytoplasmic domain,
involving the third FNIII repeat (Fig 7).
These ¢ndings ¢t with the absent binding of monoclonal anti-
body 450^11A, which recognizes an epitope within the third
FNIII repeat of b4 to patient’s epidermis and keratinocyte extract.
In our RT-PCR analysis of the patient’s mRNA the band with
skipped exon 36 was the major product. It is likely that the 2 bp
deletion, leading to a PTC, is rescued by alternative splicing of
exon 36. The presence of the carboxy-terminal end of the protein
in the skin of the patient is in line with an in-frame skip. Immu-
noblot analysis indeed showed that the patient’s cells produced
the b4 protein of reduced size. No full-size protein was detected
on immunoblots and, given the low intensity of the upper RT-
PCR band, consisting partially if not mostly of 2 bp deleted se-
quences, the patient is also expected to be heterozygous for a null
allele. Attempts to speci¢cally amplify cDNA from this allele by
using nondeletion-site primers failed. The search for the second
mutation failed in that the analysis of genomic DNAwas unable
to disclose any pathogenic sequence variants other than the het-
Figure 4. The 450^11A epitope on the intracellular domain of integ-
rin b4 is absent in the patient’s skin. Compare the identical panel of
antibodies on the patient’s skin (A^D) and control skin (E^H). (A, E)
Monoclonal antibody 450^11A to the third FNIII repeat on the intracellu-
lar domain of integrin b4 does not stain in patient’s skin. (B, F) Monoclonal
antibody 58XB4 to the extracellular domain of integrin b4 stains the epi-
dermal BMZ in patient’s and control skin. (C, G) The integrin a6 subunit
(GoH3) is con¢ned to the epidermal BMZ (and lines the blister £oor) and
is not present in the lateral walls of basal cells in the patient’s skin. (D, H)
BP180/type XVII collagen ectodomain (NCC-Lu-226) is polarized in the
epidermal BMZ in the patient’s skin and is also present in the lateral cell
walls similar to control skin.
Figure 5. Immunoblot analysis reveals that the patient’s keratino-
cytes produce only a reduced amount of shortened integrin b4. Pro-
teins from cultured cell extracts were immunoblotted with antibodies
against integrin b4. Lanes 1, 2: Antibodies against the extracellular and in-
tracellular domains of b4, respectively, in extracts of control cells. Lane 3:
The cell extracts of the patient’s keratinocytes contained a reduced amount
of mutant b4 that reacted with the antibody against the extracellular b4
domain. Lane 4: The cell extracts of the patient’s keratinocytes did not react
with an antibody against the intracellular b4 domain. The apparent mole-
cular weight of the integrin b4 polypeptide in the patient’s cell extracts is
approximately 5 kDa smaller (n) than that of the wild-type protein.
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erozygous 2 bp deletion (Professor J. McGrath, personal commu-
nication). Nonetheless, the contribution of the other allele to pro-
tein production may be considered as very low.
Moderation of phenotypic severity by skipping of exons con-
taining nonsense mutations has been observed before (Morisaki
et al, 1993). Maintenance of the open reading frame by ribo-
some-mediate scanning of pre-mRNA transcripts for PTCs
serves as an additional level of scrutiny during splice site selection
(Dietz and Kendzior et al, 1994), and indeed, in-frame skipping of
exons containing PTCs has been reported in the COL7A1 and
LAMB3 genes in dystrophic and junctional forms of epidermoly-
sis bullosa (McGrath et al, 1999). mRNA rescue may also depend
on activation of the illegitimate splicing event during develop-
ment, explaining the amelioration with aging of the clinical phe-
notype of unique cases with Herlitz JEB (Gache et al, 2001) and
JEB-PA (Chavanas et al, 1999).This was not the case in our patient
in whom the phenotype had always been con¢ned to the hands
and feet. Interesting was the case of mild non-Herlitz JEB in
which skipping of the mutated COL17A1 exon 33 was also ob-
served, at low level, by RT-PCR analysis in control keratinocytes
(Ruzzi et al, 2001). Likewise, skipping of ITGB4 exon 36, albeit at
a very low level, was observed in control keratinocytes in our
case. Thus, restoration of the open reading frame by splicing out
the exon containing a null mutation seems more prone in situa-
tions in which the exon is spliced out at low levels in wild-type
RNA anyway.
The mild phenotype in our patient is explained by exon 36
skipping and a 50 amino acid deletion of a less critical region on
the intracellular domain of b4: the third FNIII repeat. The integ-
rin b4 subunit is characterized by an unusually long cytoplasmic
domain that harbors four FNIII repeats, residing in two pairs
separated by a connecting segment (Fig 7) (Hogervorst et al,
1990). The region comprising the ¢rst and second FNIII repeats
and the ¢rst beta4 of the connecting segment is required for the
localization of 4 into hemidesmosmes (Schaapveld et al, 1998), and
contains the plectin binding site on the second FNIII repeat
(Nievers et al, 1998; Geerts et al, 1999). Deletion of 17 residues of
the second FNIII repeat due to the 3801þ2insT splice site muta-
tion results in lethal JEB-PA (Vidal et al, 1995). Missense muta-
tions R1225H and R1281W in the second FNIII repeat clinically
result in nonlethal JEB-PA (Pulkkinen et al, 1998b; Nakano et al,
2001) and indeed prevent interaction of b4 with plectin as de-
monstrated in yeast two-hybrid assays (Koster et al, 2001). In our
patient the deletion of exon 36 (1450^1499) truncates more pre-
cisely the beginning of the third FNIII repeat (1458^1541) in the
intracellular domain of b4 integrin (Fig 7). Previous in vitro
Figure 6. RT-PCR, subcloning, and nucleotide sequencing reveals skipping of exon 36. (A) RT-PCRwith primer set 8 (Table I) ampli¢es a 532 bp
cDNA fragment in the normal control (N), but three bands in the patient (p). Exons 33 and 35 of integrin b4 are spliced out in mRNA of control kerati-
nocytes. (B) After subcloning and nucleotide sequencing the most prominent and shortest band (B) appeared to have skipped the 150 bp of exon 36. Band A
at the position of the wild-type contained the CTdeletion at position 4733.The intermediate band was a heteroduplex artifact. Note that the normal control
(N) also contains a faint type B band, suggesting that normal control keratinocytes alternatively skip exon 36 to a limited extent.
Figure 7. Molecular defect associated with the mutation 4733delTC. Schematic presentation of the integrin b4A chain in keratinocytes. The
4733delTC (italic) is shown in exon 36, and the 50 residues deletion eliminating part of the third FNIII-like repeat. sp, signal peptide; tm, transmembrane
domain; CS, connecting segment; 1, 2, 3, and 4, FNIII-like repeats.
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studies have shown that the major binding sites for BP180/type XVII
collagen are within the segment comprising the COOH-terminal
half of the connecting segment and the third FNIII repeat of b4
(residues 1320^1552) (Borradori et al, 1997; Aho and Uitto, 1998;
Schaapveld et al, 1998). b4 mutants with truncations in this region
exhibited a reduced capacity to recruit BP180, as assessed by im-
muno£uorescence analysis in cultures of transfected b4-de¢cient
keratinocytes (Schaapveld et al, 1998). In the skin of our patient
with a truncation in the third FNIII repeat of b4, however,
BP180 was normally recruited along the epidermal BMZ in basal
keratinocytes (Fig 4D). One possible explanation for this discre-
pancy is that integrin a6 may function as an alternative anchor
point for BP180 recruitment, as both molecules interact through
their extracellular domains as found by Hopkinson et al (1995;
1998). In our patient integrin a6 is expected to be localized cor-
rectly in hemidesmosmes, as integrin a6 associates in vitro with
mutant b4 lacking the third FNIII repeat (Schaapveld et al, 1998).
Another explanation is that the recruitment of BP180 in the pa-
tient may be triggered by a mechanism only present in vivo, for
instance the binding to its unknown ligand. This was also con-
cluded by Murgia et al who found partial polarization of BP180/
type XVII collagen along the epidermal BMZ in mice carrying a
targeted deletion of the b4 cytoplasmic domain (Murgia et al,
1998). The phenotype of these tail-less b4 mice resembled JEB-
PA. This severe phenotype was apparently caused by impairment
to assemble hemidesmosmes due to the lack of the plectin-bind-
ing domain in the ¢rst and second FNIII repeats. The mild phe-
notype in our patient suggests that the BP180-binding third
FNIII repeat of integrin b4 may be less critical for the function
of the hemidesmosome than the plectin-binding second FNIII
repeat.
In our patient the split level was intraepidermal, separating
plectin from the other components of the hemidesmosomal pla-
que (BP230, BP180, integrin a6b4). The primary defect in this
patient might therefore be an impaired linkage between b4 and
plectin. According to the hemidesmosome model of Sonnenberg,
binding of b4 to plectin is both direct via the second FNIII repeat
of b4 and indirect via BP180/type XVII collagen (Nievers et al,
1999). Although, plectin was polarized along the epidermal
BMZ in the patient, we speculate that the linkage of b4 to plectin
was unstable by loss of the BP180/type XVII collagen binding site
(Fig 8).
Recognizing the possibility to alternative splicing of ITGB4
exon 36 it is of interest to reevaluate previous reports on muta-
tions in this particular exon. Mellerio et al (1998) reported two
cases with mild nonlethal JEB-PA associated with mutations in
ITGB4 exon 36 (Mellerio et al, 1998). The ¢rst patient (A) was a
compound heterozygote for a splice site mutation in exon 30
(3793þ1G-to-A) and a nonsense mutation in exon 36
(W1478X), and the second (B) was a compound heterozygote
for a missense mutation in exon 3 (C38R) and a 1 bp deletion in
exon 36 (4776delG). The authors attribute the mild phenotype to
alternative splicing of exon 30 in the ¢rst patient and the missense
mutation C38R in the second patient. We hypothesize that the
mild phenotype may also be explained, however, by the bene¢-
cial skipping of exon 36 containing the other mutation in both
patients. The second JEB-PA patient (B) in particular had a level
of separation similar to our patient, with a very low plane of clea-
vage in the basal keratinocytes above the hemidesmosome pla-
ques. The same goes for the JEB-PA case (G) in the paper by
Nakano et al (2001), who was homozygous for the 2 bp deletion
4790delTC in exon 36 of ITGB4, which was a putative PTC-
causing mutation (Nakano et al, 2001). The resulting nonlethal
phenotype and the presence, although in reduced amounts, of
integrin b4 polypeptides in the patient’s skin again may not be
due to impaired mRNA nonsense decay, but to skipping of exon
36. The case (2) reported by Pulkkinen et al, who was compound
heterozygous for C738X and 4791delCA in exon 36 (putative
PTC/PTC), showed reduced expression of b4 in the skin that
was extractable withTriton X-100, suggesting an altered structur-
al organization for this mutant integrin (Pulkkinen et al, 1998b).
The level of cleavage was very low in the basal cells just above the
plasma membrane, however. None of the studies included RT-
PCR analysis of keratinocytes, however, so that our prediction
has to be brought to the bench.
What remains unexplained is why our patient did not have py-
loric atresia like the other cases reported with mutations in exon
36. Rescue by the other allele appears unlikely, as no b4 of nor-
mal size was observed in the patient’s keratinocytes in vitro. More-
over, the 450^11A epitope was not expressed in the patient’s
keratinocytes in vivo. The absence of intestinal involvement in
our patient is also not explained by the possibility of an intestinal
b4 isoform that alternatively splices out the third FNIII repeat.
Human intestinal cells express the full-length b4A isoform that
contains the third FNIII repeat (Basora et al, 1999). The question
on pyloric involvement needs further research.
The genetic, biochemical, and clinical data obtained here ex-
tend the spectrum of the phenotypic heterogeneity of EB. It asks
for new appositions in the classi¢cation of EB. This work also
underlines the importance of using intracellular and extracellular
domain speci¢c integrin b4 antibodies for assessment by antigen
mapping of EB patients.
We wish to thank the following scientists for the donation of antibodies: 450^11A and
439^9B, kind gifts of Dr. S.J. Kennel, Oak Ridge; GoH3 and 58XB4, kind gifts of
Dr. A. Sonnenberg, Amsterdam; J143, kind gift of Dr. M.E. Hemler, Boston;TS2/
16, kind gift of Dr. F. Sanchez-Madrid, Madrid; 1A8c, 1D1, HD121, and 815, kind
gifts of Dr. K. Owaribe, Nagoya; NCC-Lu-226, kind gift of Dr. S. Hirohashi, To-
kyo; GB3, kind gift of Dr. G. Meneguzzi, Nice; 19-DEJ-1, kind gift of Dr. J.D.
Fine, Chapel Hill; LH7:2, kind gift of Dr. I. Leigh, London. Professor J. McGrath
is thanked for genomic screening of the integrin b4 gene in the patient.
ELECTRONIC DATABASE INFORMATION
Accession numbers and URLs for data in this paper are as fol-
lows: http://www.ncbi.nlm.nih.gov/GenBank/ (for ITGB4 [ac-
cession number NM_000213] and for integrin b4A [accession
number NP_000204]); Online Mendelian Inheritance in Man,






















Figure 8. Putative disturbance of the molecular interactions in pa-
tient’s hemidesmosomes. According to the integral hemidesmosome
model of Sonnenberg (Nievers et al, 1999), loss of the third FNIII-like re-
peat of integrin b4 would pertubate the intracellular interaction between
integrin b4 and BP180/type XVII collagen.
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